Luz Figueroa-Escalera, APRN
Adult Health · Wesley Chapel, FLNPI 1629483300
Payments from drug & device makers
Across 339 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$784
- Novartis$640
- Abbott$627
- Esperion Therapeutics, Inc.$569
- Boehringer Ingelheim$527
- E.r. Squibb & Sons, L.L.C.$461
- plus $4K from 33 others
What the payments were for
- Food & beverage$7,370100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 53 | $784 |
| Novartis | 38 | $640 |
| Abbott | 12 | $627 |
| Esperion Therapeutics, Inc. | 33 | $569 |
| Boehringer Ingelheim | 15 | $527 |
| E.r. Squibb & Sons, L.L.C. | 21 | $461 |
| Pfizer | 22 | $453 |
| Atricure, Inc. | 5 | $390 |
| Amarin Pharma, Inc. | 22 | $337 |
| AstraZeneca | 14 | $273 |
| Johnson & Johnson(2 entities) | 12 | $233 |
| Cvrx, Inc. | 6 | $223 |
| Boston Scientific | 10 | $199 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $187 |
| Impulse Dynamics (USA) Inc. | 2 | $178 |
| Novo Nordisk | 9 | $175 |
| Mallinckrodt Hospital Products Inc. | 8 | $173 |
| Medtronic | 6 | $153 |
| Alnylam Pharmaceuticals Inc. | 4 | $125 |
| Philips North America LLC | 3 | $70 |
| Bayer | 3 | $69 |
| Actelion Pharmaceuticals US, Inc. | 2 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Sobi, Inc | 2 | $39 |
| Astellas Pharma US Inc | 2 | $39 |
| Azurity Pharmaceuticals, Inc. | 2 | $37 |
| Irhythm Technologies, Inc. | 2 | $34 |
| Biotronik Inc. | 1 | $34 |
| Baxter Healthcare | 2 | $32 |
| Merck | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Edwards Lifesciences | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $20 |
| UCB, Inc. | 1 | $16 |
| GSK | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$312
- OPTIMIZER$265
- CAMZYOS$256
- MERLIN@HOME$184
- ASSURITY$154
- Barostim Neo System$120
- JARDIANCE$120
How this compares
$7,370 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 372 | $422,167 |
| Repatha SureclickEvolocumab | 80 | $88,323 |
| XareltoRivaroxaban | 52 | $73,670 |
| EntrestoSacubitril/Valsartan | 48 | $45,974 |
| MultaqDronedarone Hcl | 24 | $26,861 |
| Repatha SyringeEvolocumab | 20 | $26,798 |
| FarxigaDapagliflozin Propanediol | 26 | $19,062 |
| VascepaIcosapent Ethyl | 21 | $16,737 |
| Praluent PenAlirocumab | 24 | $15,317 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $12,932 |
| JardianceEmpagliflozin | 12 | $10,741 |
| Ranolazine ErRanolazine | 138 | $10,622 |
| Icosapent Ethyl | 21 | $9,990 |
| Droxidopa | 11 | $6,500 |
| Clonidine | 40 | $6,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $453 | $422,167372 claims |
| Johnson & JohnsonXarelto | $233 | $73,67052 claims |
| NovartisEntresto | $640 | $45,97448 claims |
| Sanofi-aventis U.S. LLCMultaq | $28 | $26,86124 claims |
| AstraZenecaFarxiga | $273 | $19,06226 claims |
| Esperion Therapeutics, Inc.Nexlizet | $569 | $12,93213 claims |
| Boehringer IngelheimJardiance | $527 | $10,74112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Wesley Chapel
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.